Stoke Therapeutics Q2 net loss $25.7M; FDA lifts partial clinical hold on zorevunersen

Stoke Therapeutics, Inc.

2024-Q2 EPS reported -$1.02 revenue$9,048,000

FDA removed Partial Clinical Hold on zorevunersen for Dravet syndrome; planning Phase 3 registrational study.
Q2 revenue $4.8M (vs. -$2.5M prior year); net loss $25.7M ($0.46/shr) vs. $30.7M ($0.69/shr) prior year.
Cash, cash equivalents, and marketable securities totaled $282M as of June 30, 2024.
On track to initiate Phase 1 OSPREY study of STK-002 for Autosomal Dominant Optic Atrophy in 2024.
Regulatory discussions ongoing; update on Phase 3 registrational plans for zorevunersen expected H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.